- Signaling Pathways
- JAK/STAT Signaling MAPK/ERK Pathway PI3K/Akt/mTOR
- Erythropoietin Receptor (EpoR)
Erythropoietin Receptor (EpoR)
Erythropoietin Receptor; EpoR
Erythropoietin receptor (EpoR) is a receptor present on erythroid progenitor cells, belonging to the type I cytokine receptor family and characterized by a single transmembrane domain. When EpoR binds to erythropoietin (EPO), it effectively inhibits cell apoptosis and stimulates the production of red blood cells.
Activation of EpoR leads to the activation of downstream intracellular signaling pathways, including the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) pathway, the mitogen-activated protein kinase (MAPK) pathway, and the signal transducer and activator of transcription (STAT) pathway.
In erythroid lineage cells, the expression of EpoR is crucial for the normal development of mammals. Furthermore, EpoR plays a pivotal role in the complex cascade responses to acute and chronic hypoxic injuries in the body, particularly within the cardiovascular system. EpoR has driven research into the beneficial effects of erythropoietin in various diseases, primarily cardiovascular diseases[1].
All Product Categories
-
Erythropoietin Receptor (EpoR) Related Products (2)
Related Products (2)
By Targets:
Loading...
Show More (1)
By Effects:
Loading...
By Disease Areas:
Loading...
Show More (5)
Erythropoietin Receptor (EpoR) Related Products
Related Products
Clear Filters
- STS-E412
-
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
ASP7967 hemifumarate
0 ImagesCat. No.: HY-49538CCAS No.: 1246958-42-8ASP7967 hemifumarate is an orally active ligand of the RNA aptamer AC17-4 with a Kd of 12 nM. ASP7967 hemifumarate binds AC17-4 to regulate aptazyme-based and exon-skipping riboswitches, thereby enabling small-molecule-controlled transgene expression without exogenous protein factors. ASP7967 hemifumarate can be used for the study of synthetic RNA switches, gene expression regulation and AAV-based gene therapy-related expression control. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -